Cardiovascular Outcomes and Readmissions in Patients With Mitraclip With Acute Heart Failure
Author Type(s)
Resident/Fellow
Document Type
Abstract
Publication Date
2022
Journal Title
Journal of the American College of Cardiology
Department
Medicine
Abstract
Background: Acute heart failure (AHF) is a common presentation; however, the outcomes after MitraClip (Abbott Vascular) placement in patients presenting with AHF remain largely unknown. We investigated the impact of AHF on readmissions and outcomes after MitraClip placement. Methods: We queried the National Readmission Database from 2015 to 2018 using International Classification of Diseases-10th Revision codes to compare patients receiving the MitraClip who had readmissions with AHF versus patients who did not have AHF. Cardiovascular outcomes were assessed between 2 cohorts at index admissions and readmissions using chi-square statistics in software STATA v.17 (StataCorp LLC). Results: A total of 16,591 patients who had undergone MitraClip placement were included in the analysis. Among the patients who received the MitraClip, patients readmitted with AHF (6,037) had worse clinical outcomes with increased incidence of major complications (37% vs 12%), acute kidney injury (33% vs 9%), major adverse cardiovascular and cerebrovascular events (15% vs 3%), and nonhome discharge (17.5% vs 6%) compared with patients without AHF (10,554). In the multivariate analysis with adjusted OR, we found that there are increased odds of having major adverse cardiovascular and cerebrovascular events (3.88), acute kidney injury (3.07), myocardial infarction (4.86), and in-hospital mortality (2.06) among the patients with AHF compared with patients without AHF (P < 0.001 for all). Rates of readmissions were higher in the AHF cohort at 30 days, 90 days, and 180 days (18.67% vs 12.18%, 25.36% vs 18.24, and 21.91% vs 16.52%). The average length of stay was significantly higher in AHF versus without AHF (3.6 vs 11.0 days). [Formula presented] Conclusion: AHF was found to be associated with adverse clinical outcomes and higher rates of readmissions (up to 180 days) in patients who had undergone the MitraClip procedure for the treatment of MR. Categories: STRUCTURAL: Valvular Disease: Mitral
Recommended Citation
Pandya, K., Sattar, Y., Titus, A., Patel, N., Erdem, S., Bdiwi, M., Patel, N., Fakhra, S., Dandu, C., Alyami, B., Victor, V., & Alraies, M. C. (2022). Cardiovascular Outcomes and Readmissions in Patients With Mitraclip With Acute Heart Failure. Journal of the American College of Cardiology, 80 (12), B170. https://doi.org/10.1016/j.jacc.2022.08.496
